PanNASH covers commented articles ans publications to acquire sufficient information, understanding, and skills to cope with NASH/NAFLD healthcare demands.
Understanding the drivers of non-alcoholic fatty liver disease (NAFLD) is crucial to developing pharmacotherapies that effectively target it. Insulin resistance (IR), whose onset precipitates type 2 diabetes (T2D), is known to play a crucial role in the development of hepatic steatosis.
The multinational liver societies introduce a non-stigmatizing and affirming nomenclature for "Fatty" liver diseases, striving for a global consensus to advance research, funding, and patient care.
Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of pathologies ranging from simple steatosis to steatohepatitis (NASH) and fibrosis.
Disease awareness, patient stratification, diagnosis, and access to care are all helped or hindered by a pathology’s nomenclature. Indeed, the language used to name and identify a disease has the power to create or intensify social stigma, marginalise subsets of a patient population, and perpetuate health inequalities.
Models of care (MoCs) establish comprehensive frameworks for the provision of healthcare services along a continuum of care.
Recent research into liver disease indicates that muscle health is often compromised in its later stages.
According to transient elastography-derived data, non-alcoholic fatty liver disease (NAFLD)’s prevalence in the United States (US) has increased from 18% in 1988-1991 to an estimated 25-50% in recent years.
Patients with non-alcoholic fatty liver disease (NAFLD) exhibit alterations in their gut microbiota composition. Indeed, both nuclear and mitochondrial DNA methylation have been linked to the development of NAFLD and metabolic diseases, including obesity and type 2 diabetes mellitus.
Previous studies investigating non-invasive tools for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), its inflammatory subtype, have demonstrated the clear diagnostic efficacy of liver stiffness measurement by vibration-controlled transient elastography (LSM-VCTE).
Generally, NASH and fibrosis correlate with the development of cirrhosis and other negative clinical outcomes. Treatments often aim to target inflammation, fibrosis, cell injury or metabolic dysregulation.
Interventional trials for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), its inflammatory subtype, are often limited by patient heterogeneity and, hence, response variability.
Despite its global prevalence of 25%, no pharmacotherapies have yet been approved to treat non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH), its inflammatory subtype.